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Abstract
Despite increasing evidence that autoreactive CD8 T-cells are involved in both the initiation of type 1 diabetes (T1D) and the
destruction of beta-cells, direct evidence for their destructive role in-vivo is lacking. To address a destructive role for
autoreactive CD8 T-cells in human disease, we assessed the pathogenicity of a CD8 T-cell clone derived from a T1D donor
and specific for an HLA-A2-restricted epitope of islet-specific glucose-6-phosphatase catalytic-subunit related protein (IGRP).
HLA-A2/IGRP tetramer staining revealed a higher frequency of IGRP-specific CD8 T-cells in the peripheral blood of recent
onset human individuals than of healthy donors. IGRP265–273-specific CD8 T-cells that were cloned from the peripheral blood
of a recent onset T1D individual were shown to secrete IFNc and Granzyme B after antigen-specific activation and lyse HLA-
A2-expressing murine islets in-vitro. Lytic capacity was also demonstrated in-vivo by specific killing of peptide-pulsed target
cells. Using the HLA-A2 NOD-scid IL2rcnull mouse model, HLA-A2-restricted IGRP-specific CD8 T-cells induced a destructive
insulitis. Together, this is the first evidence that human HLA-restricted autoreactive CD8 T-cells target HLA-expressing beta-
cells in-vivo, demonstrating the translational value of humanized mice to study mechanisms of disease and therapeutic
intervention strategies.
Citation: Unger WWJ, Pearson T, Abreu JRF, Laban S, van der Slik AR, et al. (2012) Islet-Specific CTL Cloned from a Type 1 Diabetes Patient Cause Beta-Cell
Destruction after Engraftment into HLA-A2 Transgenic NOD/SCID/IL2RG Null Mice. PLoS ONE 7(11): e49213. doi:10.1371/journal.pone.0049213
Editor: Paolo Fiorina, Children’s Hospital Boston/Harvard Medical School, United States of America
Received April 20, 2012; Accepted October 5, 2012; Published November 14, 2012
Copyright:  2012 Unger et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study has been supported in part by grants from the Juvenile Diabetes Research Foundation Program Grant (7-2005-877 to BOR, WWJU, SL and
JWD), the Dutch Diabetes Research Foundation DFN (to JRFA), National Institutes of Health Grant AI46629 (and an institutional Diabetes Endocrinology Research
Center (DERC) grant DK32520, the Beta Cell Biology Consortium, a grant from the Helmsley Foundation and the Dutch Diabetes Research Foundation. BOR is
recipient of a VICI award (ZonMW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: boroep@lumc.nl
¤ Current address: Department of Molecular Cell Biology and Immunology, VUmc, Amsterdam, The Netherlands
. These authors contributed equally to this work.
Introduction
Non-obese diabetic (NOD) mice are widely used for studying
the pathogenesis and therapy of autoimmune type 1 diabetes
(T1D) [1]. Autoreactive CD4 and CD8 T-cells in NOD mice
infiltrate and subsequently destroy the insulin-producing beta-cells
in pancreatic islets, resulting in dysregulation of blood glucose
levels and hyperglycemia [2;3]. Although studies using NOD mice
have helped to define mechanisms of disease pathogenesis and to
identify potential interventional and therapeutic strategies in
autoimmune diabetes, there are discrepancies between disease
pathogenesis in NOD mice and in humans. For example, while the
lymphocytic infiltrate in the NOD pancreas is extensive, insulitis in
humans is multi-focal and targets islets scattered throughout
a pancreas [1;4].
The recruitment of autoreactive CD4 T-cells is required for the
initiation of autoreactivity in NOD mice, yet CD8 T-cells are
increasingly being recognized as key pathogenic mediators in the
destruction of beta-cells and progression of the disease in both
diabetic NOD mice and humans [5–11]. Deficiency of CD8 T-
cells due to the absence of MHC class I in NOD mice renders
these mice completely resistant to T1D [6;7]. In humans,
susceptibility to T1D is strongly associated with the HLA-A2
haplotype, with 60–70% of affected individuals expressing this
allele [12]. Transgenic expression of HLA-A2 significantly
accelerates disease onset in NOD mice, and is associated with
the early appearance of HLA-A2-restricted CD8+ T-cells in
prediabetic insulitic lesions [13].
The epitopes recognized by autoreactive cytotoxic T-cells are
thought to be primarily derived from beta-cell proteins, and the
identity of these epitopes in humans remains under active
investigation. A known target of autoreactive CD8 T-cells in the
NOD mouse is islet-specific glucose-6-phosphatase catalytic-sub-
unit related protein (IGRP) [14;15]. Several epitopes from IGRP
have been identified using HLA-A2 transgenic (Tg) NOD mice
[16], and some of these epitopes are also targeted by CD8 T-cells
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in T1D individuals [17;18]. In addition, the IGRP-specific CD8
T-cells from HLA-A2 Tg NOD mice lyse human HLA-A2+ beta-
cells in-vitro, demonstrating the potential utility of HLA-A2 Tg
NOD mice for identifying HLA-restricted islet autoantigens and
for investigating the pathogenesis of human T1D [16].
To date, however, direct evidence that human diabetogenic
CD8 T-cells target beta-cells in-vivo is lacking. The diabetogenic
role of CD8 T-cells was suggested by correlation between
increased frequencies of islet autoreactive CD8 T-cells in T1D
islet allograft recipients that exhibited recurrent islet autoimmunity
and loss of graft beta-cell function [11]. Furthermore, islet-
autoreactive CD8 T-cells from individuals reactive with pre-
proinsulin selectively killed human islet cells in-vitro in a glucose
concentration-dependent fashion, suggesting cross-talk between
the immune system and pancreatic beta-cells [19]. Very recently,
we could demonstrate the presence of IGRP-specific CD8 T cells
in insulitis lesions of human T1D patients, which is strong
indication for their role in the beta-cell destruction process in
humans [20]. To close the critical gap in knowledge of disease
mechanisms in T1D in humans, novel preclinical models are
needed to investigate the pathogenicity of human autoreactive T-
cells in-vivo. Recently, NOD-scid IL2rcnull mice have been de-
veloped [21–23] that readily engraft with human PBL [24] and are
transgenic for HLA-A2 [25;26].
We and others have shown that human HLA-A2-restricted
CD8 T-cells can recognize the IGRP265–273 epitope conserved
between mice and humans [18;27]. To test the involvement of
CD8 T-cells specific for this epitope in beta-cell destruction, we
cloned these cells from the peripheral blood of a recent onset T1D
individual. We then used the new generation of HLA-A2 Tg
immunodeficient humanized mice to assess the pathogenicity of
human effector immune cells in-vitro and in-vivo [28].
Results
IGRP265–263-specific CD8 T-cells Cloned from the Blood of
Type 1 Diabetic Individuals are Effector CTLs
IGRP265–273 has been identified as an epitope of islet
autoreactive CD8 T cells using NOD-b2mtm1Unc HHD Tg mice
that express a chimeric HLA-A2.1/H-2Db molecule [16]. To
assess potential involvement of CD8 T-cells specific for this epitope
in islet-cell destruction in-vivo, IGRP265–273 cells were cloned from
the peripheral blood of a recent onset T1D individual. Selective
binding of this epitope to HLA-A2 was determined (Figure S1).
Using A2/IGRP tetramers and CD8 antibodies, IGRP-specific
CD8 T-cells were identified in PBMC of HLA-A2+ recent onset
individuals but not of healthy controls, confirming previous
findings (Figure 1A). Double positive cells were sorted at one cell
per well and stimulated using peptide-pulsed APC and feeders.
Three weeks later, IGRP-specific CD8 T-cell clones were
identified that stained with HLA-A2-specific tetramer but not
with an HLA-A2-control tetramer (Figure 1B).
From the available clones, we selected one for further
characterization. Analysis of clone 7 TCR-Va and -Vb transcripts
using specific primers revealed message for Va19 and Vb13 only,
which, in combination with VDR3 length variation analysis,
confirmed clonality of this T-cell population (Table S1). Clone 7
T-cells (hereafter referred to as IGRP-specific T-cells) expressed
markers necessary for strong antigen recognition (CD2 and
CD28), as well as the activation- and memory markers HLA-
DR and CD45RO (Figure S2). Activation of the IGRP265–273-
specific T-cells with their cognate antigen resulted in secretion of
IFNc but not IL-10 (Figure 1C). No cytokine production was
detected when APC were loaded with a control HLA-A2 binding
peptide, demonstrating the antigen specificity of these T-cells
(Figure 1C). In addition, IGRP-specific T-cells produced IL-2 and
TNFa upon antigen-specific activation, but not IL-4 (data not
shown), endorsing these cells with an overt effector phenotype
[29]. Furthermore, antigen-specific activation of these CD8 T-cells
led to cytotoxic activity as shown by expression of CD107a, which
is present in the membrane of cytotoxic granules, production of
GrB as well as lysis of peptide-pulsed HLA-A2+ target-cells
(Figure 1C,D and 2A). The efficacy of the IGRP-specific T-cell
clone to recognize the IGRP265–273 epitope was demonstrated in
peptide-dose titration cytotoxicity assays, indicating that the
IGRP-specific T-cell clone had a relatively low avidity for its
ligand, since 1 mM peptide was required to attain 50% of the
maximal response (Figure 2B). A hallmark of low-avidity T-cells is
CD8-dependent binding of peptide/MHC complexes [30;31].
Anti-CD8 antibody completely blocked tetramer labeling
(Figure 2C). Furthermore, T-cells stained negative with
IGRP265–273 tetramers of HLA-A2 molecules mutated in their
CD8-binding a3 region [32;33].
Lysis of HLA-A2 Expressing Murine Islets in-vitro
We next examined the potential of the IGRP-specific T-cell
clone to recognize naturally processed and presented IGRP
epitope by testing its reactivity with HLA-A2 expressing murine
islets. Since dissociated islet-cells exhibit a high degree of
spontaneous death that can complicate data interpretation, we
used a previously described assay in which intact islets are allowed
to adhere and form monolayers before use [16]. We observed
highly efficient islet cell killing of NOD-scid HHD Tg islets, even at
very low effector:target (E:T) ratios (Table 1), approximately 15%
of the NOD-scid. HHD Tg islet cells were lysed at an E:T ratio of
30, whereas only 0.6% HLA-A2-negative islets were killed
(P,0.01). Lysis of NOD-scid HHD islets by IGRP-specific CD8
T-cells was significantly greater than with HLA-A2-restricted
tumor-antigen-specific CD8 T-cells (Table 1).
Human IGRP-specific CD8 T-cells Lyse Peptide-pulsed
Target Cells in-vivo
To determine the cytotoxic activity of IGRP-specific CD8 T-
cells in-vivo, we adapted a murine in-vivo cytotoxicity assay that is
widely used to demonstrate cytotoxic actions of primed effector/
memory CD8 T-cells [34;35]. HLA-A2+ target cells (PBMC) were
labeled with different concentrations of CFSE, pulsed with either
IGRP265–273 or irrelevant peptide, mixed and injected into NOD-
scid IL2rcnull mice that had received an intrasplenic injection of
IGRP-specific T-cells 24 h earlier. Mice that had not been injected
with the human T-cell clone were used as a negative control.
IGRP-specific T-cells lysed IGRP-pulsed target cells in-vivo, as
demonstrated by the specific disappearance of the CFSEhi-labeled
target cells pulsed with IGRP-peptide (Table 2). In contrast, the
number of CFSElo-labeled targets pulsed with control peptide
remained unchanged, even in the presence of the IGRP-specific
T-cells.
Intra-pancreatic Injection of IGRP-specific T-cells into
NOD-scid IL2rcnull HHD Mice Leads to Infiltration and Islet
Disruption
We next investigated whether human IGRP-specific CD8 T-
cells can target and destroy HLA-A2 pancreatic beta-cells in-vivo.
The expression of both CD62L and the chemokine receptors
CXCR3 and CCR4 (Figure S2) indicates that the IGRP-specific
T-cells express adhesion markers required to migrate to secondary
lymphoid tissue and inflamed pancreatic tissue [36;37]. Since
Human Islet-Specific T-Cells Kill Islets In Vivo
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NOD-scid IL2rcnull HHD mice are devoid of cytokines necessary for
homeostatic T-cell proliferation, we hypothesized that the survival
of the human CD8 T-cell clone would be facilitated by injecting
human PBMC from non-diabetic donors 48 h earlier. This time
span would be sufficient for the PBMC to expand in the
lymphopenic environment and produce the necessary cytokines
that may be required for survival of cloned CD8 T-cell in the
absence of CD4 T-cell help. As a control, a diabetes-unrelated
CD8 T-cell clone was injected intrapancreatically. Additional
control mice received a sham-injection.
No changes in blood glucose levels were detected following
injection of either IGRP-specific or control T-cell clones (data not
shown). Four weeks after adoptive transfer of the human T-cell
clones the pancreas was recovered and analyzed by histology for
islet integrity and presence of the IGRP-specific CD8 T-cells. Both
human IGRP-specific and control CD8 T-cells were present at
detectable levels four weeks after injection (Figure 3A). However,
their location differed greatly. Pancreata of recipient mice of
IGRP-specific T-cells predominantly elicited intra-islet infiltration
(Figure 3A). In contrast, control CD8 T-cells remained at the
perivascular sites. Mice receiving a sham injection showed no
infiltration of islets. Notably, insulin staining of pancreatic sections
revealed that the islets were disrupted only in mice injected with
the IGRP-specific T-clone, but not in those receiving the control
CD8 T-cells or a sham injection (Figure 3A). The number of islets
infiltrated with T-cells was significantly greater in mice injected
with the IGRP T-clone, 10/49 (20%) than mice injected with the
control T-clone, where none of 20 investigated islets showed
infiltrating cells, although T-cells were occasionally found around
the islets. (p = 0.013; two-tailed Fisher exact test). Moreover,
absence of insulin staining was accompanied by positivity for
cCaspase-3, pointing to beta-cell destruction by IGRP-specific T-
cells (Figure 3B). Pancreata of mice that received control CD8 T-
cells were negative for cCaspase-3 staining.
Discussion
This study provides the first evidence that autoreactive CD8 T-
cells cloned from a T1D individual can participate in islet cell
destruction in-vivo using a novel humanized mouse model.
IGRP265–273-specific CD8 T-cells producing IFNc and expressing
CD107a upon antigen-specific activation are capable of lysing
murine HLA-A2 expressing islets in-vitro. In-vivo, these T-cells lysed
target cells pulsed with islet peptide. Following intra-pancreatic
injection into HLA-A2 transgenic NOD-scid IL2rcnull HHD mice,
IGRP-specific CTLs localized to the islets and caused beta-cell
destruction. However, no changes in blood glucose-levels were
observed. No islet cell destruction was detected when mice were
injected with equal numbers of control HLA-A2-restricted cloned
CD8 T-cells.
The assumption that IGRP-specific CD8 T-cells possess di-
abetogenic potential in-vivo was based on the observation that these
cloned T-cells were highly cytotoxic for HLA-A2 expressing islets
in-vitro. However, the extent of lysis observed was low in
comparison to lysis of peptide-pulsed EBV-LCL. This difference
might be explained by lower expression of HLA-A2 molecule
(HHD) on murine islets compared with HLA-A2 levels on human
cells, which consequently results in decreased presentation of the
IGRP epitope. In addition, the IGRP-specific T-cells possess low-
avidity T-cell receptors as revealed by low staining with specific
tetramer and CD8 dependency of tetramer staining. This may be
inherent to autoreactive T-cells, since these should have been
eliminated during thymic education due to high-avidity interac-
tions with their cognate self-antigen. Thus, besides weak recogni-
tion of the epitope by the low-avidity TCR of the IGRP-specific T-
cells, these observations are also consistent with low amount of
IGRP epitope presentation on the surface of the islets.
Using an adapted in-vivo cytotoxicity assay, we obtained
evidence that IGRP T-cells are capable of lysing targets in-vivo.
Mobilization of effector CD8 T-cells to infected tissue requires
CD4 T-help [38], however, CD4 T-cells only provide this help
when specifically activated by their cognate antigen at this site
[39]. Given that human IGRP-specific CD4 T-cells were not
available, we opted to inject the IGRP-specific CD8 T-cells intra-
pancreatically and to provide the optimal cytokine milieu for
survival of the transferred T-cells by systemic injection of HLA-
A2+ PBMC from non-diabetic donors prior,for generation of the
necessary cytokines (i.e. IL2, IL7, IL15) needed for T-cell
homeostasis.
Immunohistochemical analysis of the pancreata four weeks after
injection of the human CD8 T-cells revealed clear differences in
localization between the IGRP-specific T-cells and control T-cells.
IGRP-specific CTLs infiltrated into the islets, whereas control T-
cells were retained in the peri-vascular areas. Our observation
confirms previous findings that islet antigen expression is a key
factor in governing the ability of the autoantigen-specific T-cells to
accumulate in the islets [36;40;41]. Interestingly, both CD4 and
CD8 T-cells migrating into pancreatic tissue expressed the
chemokine receptor CXCR3, while distressed beta-cells produce
its ligand CXCL-10 (IP-10) [42]. This feature may present a master
switch for migration of islet autoreactive T-cells to the beta-cell
environment, as suggested by preclinical studies [43]. Some
human leukocytes were noted in the exocrine pancreatic tissue in
both mice injected with IGRP-specific T-cells and control T-cells,
which may be partly due to their intrapancreatic injection causing
tissue damage and chemokine production leading to inflammatory
infiltrates. The CD45 staining will target the injected T-clones as
well as co-injected PBMC. Yet, since the same PBMC donor was
used for all three T cells clones, the insulitis lesions could be
attributed to the particular humans T-cell clones injected, rather
than the PBMC that were not as feeders of the CD8 T cells.
Injection of the IGRP-specific T-cells resulted in a destructive
inflammation, but not when a high number of cells from a control
Figure 1. IGRP265–273-specific T-cells cloned from the peripheral blood of type 1 diabetic individuals. A, PBMCs from a HLA-A*0201
+
recent onset diabetic patients (left panel) and HLA A*0201+ healthy donors (right panel) were incubated with A2/IGRP tetramers, followed by
incubation with anti-CD8. CD8/tetramer double positive T cells were only detected in PBMC obtained from type 1 diabetic individuals and were not
detected in the blood obtained from healthy controls. B, CD8/tetramer double positive T-cells were sorted at one cell per well and clones were
picked. IGRP-specific T-clones stained with IGRP specific tetramers were observed in wells derived from type 1 diabetic individuals (left panel). These
clones did not bind control HLA-A2 tetramers (right panel). C, To assess their cytokine production profile, T-cells were incubated with IGRP peptide-
pulsed or control peptide-pulsed HLA-A2 EBV-LCL on anti-IFNc; anti-GrB and anti-IL10-coated ELISpot plates. Shown is the average number of spots
of triplicate wells. Data are representative of 3 independent experiments. * indicates significant difference from controls, P,0.01. D, IGRP-specific T-
cells were incubated with control peptide-pulsed (dashed line) or IGRP peptide-pulsed HLA-A2 EBV-LCL in the presence of anti-CD107a (grey
histogram) antibodies. As a control, T-cells were incubated with IGRP peptide-pulsed target cells in the presence of isotype control antibodies (black
line) for 5 hours. T-cells were stained for CD8 and expression of CD107a was analyzed on CD8+ T-cells using flow cytometry. Results are representative
of 2 independent experiments.
doi:10.1371/journal.pone.0049213.g001
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HLA-A2-restricted CD8 T-cell clone were injected. Since no
changes in blood glucose-levels of the recipient mice were
observed upon injection of the IGRP-specific T-cells in spite of
clear islet cell destruction, we speculate that adoptive transfer of
islet-specific CD4 T-cells may be required for propagation and
sustained CD8 T-cell expansion and cytotoxic activity [44]. A
recent study employing the same HLA-A2 NOD-scidIL2rcnull
mouse model showed that high frequencies of CD4 T-cells were
present when mice were engrafted with PBMC from a T1D
patient [45]. This was paralleled by the presence of diabetogenic
epitope-specific CD8 T-cells. However, in this study no islet cell
destruction was demonstrated, which may be due to lower
frequency of islet-specific T-cells in the pancreas compared to
our study. Yet, the fact that IGRP265–273-reactive CD8 T-cells
were present among the islet-specific CD8 T-cells, as well as the
recent finding that specific targeting of IGRP-reactive CD8 T-cells
effectively inhibited diabetes development in NOD.b2mnull.HHD
mice [46] corroborate our current findings that this epitope is
pathogenic in human disease.
T-cell autoreactivity may require more than 4 weeks for
complete beta cell destruction, and require CD4 T-cells acting in
concert. Indeed, the limited survival of CD8 T-cell clones in mice
in the absence of CD4 T-cells underscores this notion. Mouse
CD4 T-cells specific for a low-affinity insulin-derived peptide
required 20 weeks before hyperglycemia developed in 50% of
recipient mice [47]. Despite the great value of immunocompetent
NOD mice, there are discrepancies between the etiopathogenesis
of T1D in NOD mice versus humans. These differences include
the pattern of insulitis. The intra-islet infiltration pattern of human
islet-specific T-cells and islet destruction observed in our study
closely resembles the pathogenesis found in human inflamed
pancreas [4;20] rather than inflammatory lesion typically observed
in NOD mice [1;4]. The relevance of islet autoreactive T-cells
circulating in the blood in the pathogenesis of insulitis in humans
remains unresolved. Nonetheless, our current study on human
peripheral blood CD8 T-cell clones, as well as our earlier studies
on homing of human anti-islet CD4 T-cells clones to pancreatic
tissue, imply that circulating human T-cells can contribute to
insulitis. Recent studies on islet autoreactivity in an explanted
human pancreas graft indicated that circulating islet-antigen
autoreactive CD8 T-cells in peripheral blood were also present
in pancreatic inflammatory lesions, albeit at a lower frequency.
Moreover, additional islet autoreactivities that were below de-
tection levels in the circulation could be detected in the inflamed
pancreas [48].
In conclusion, our data provide first evidence that human autoreactive CD8
T-cells have the potential to target HLA-A2-matched beta-cells in-vivo,
demonstrating the translational value of humanized mice to study mechanisms
of disease and interventional strategies.
Materials and Methods
Mice
NOD.Cg-Prkdcscid Il2rgtm1Wjl/Sz (abbreviated as NOD-scid
IL2rcnull) [21], NOD.Cg-Prkdcscid (abbreviated as NOD-scid) [49]
and NOD.Cg-Prkdcscid Tg(HLA-A/H2-D/B2M)1Dvs/Dvs (abbre-
viated as NOD-scid HHD) [16] mice were obtained from The
Jackson Laboratory (Bar Harbor, ME). NOD.Cg-Prkdcscid
Il2rgtm1Wjl Tg(HLA-A/H2-D/B2M)1Dvs/DvsSz (abbreviated as
NOD-scid IL2rcnull HHD) were generated by crossing NOD.Cg-
Prkdcscid Il2rgtm1Wjl/Sz mice with NOD.Cg-Prkdcscid Tg(HLA-A/H2-
D/B2M)1Dvs/Dvs and selecting for homozygosity of the Il2rcnull
mutation and presence of the HHD transgene. HHD transgenics
were maintained in a hemizygous fashion and evaluated for
presence of the transgene by PCR or flow cytometry on peripheral
blood before use in experiments. Mice at The University of
Massachusetts Medical School and at The Jackson Laboratory
were housed in a specific pathogen free facility in microisolator
cages, and given autoclaved food and maintained on acidified
autoclaved water and sulfamethoxazole/trimethoprim medicated
water (Goldline Laboratories, Ft. Lauderdale, FL), provided on
alternate weeks. All animal use was in accordance with the
guidelines of the Institutional Animal Care and Use Committee
(IACUC) of the University of Massachusetts Medical School and
The Jackson Laboratory and conformed to the recommendations
in the Guide for the Care and Use of Laboratory Animals.
Peptide Synthesis and Generation of HLA-A2-peptide
Tetramers
Peptides were synthesized using Fmoc amino acids and PyBop/
NMM chemistry. Synthetic peptides were analyzed by reversed
phase HPLC (purity was at least 85%) and Maldi-Tof mass
spectrometry (expected masses were confirmed). Tetrameric HLA-
A2-peptide complexes were prepared as previously described [50].
Figure 2. Low-avidity IGRP-specific T-cells exhibit lytic activity in-vitro. A, Lytic capacity of the IGRP-specific T-cell was examined in
a standard 4 h cytotoxicity assay. 3000 51Cr labeled HLA-A2+ IGRP- (black dots), control-(grey squares) or non-peptide (white dots) pulsed targets
were incubated with the IGRP-specific T-cells at the indicated ratios. B, Avidity of the IGRP-specific T-cells was examined by titrating the amount of
specific (black dots) or control peptide (grey squares) on peptide-pulsed HLA-A2+ target cells. C, Tetramer staining in the presence of anti-CD8
antibody. IGRP-specific CTLs were tested 15 days after the last antigenic stimulation. Cells were labelled with A2/IGRP tetramer in the absence (left
plot) or presence of an anti-CD8 antibody (1 mg/ml of SK1; BD Biosciences; middle plot), or T-cells were incubated with a mutated IGRP/A2 tetramer
(right plot). After tetramer labelling T-cells were stained with anti-CD8 and expression was analysed by flow cytometry. Examples shown are
representative of 3 independent experiments.
doi:10.1371/journal.pone.0049213.g002
Table 1. IGRP-specific T-cells lyse HLA-A2-positive islets in-
vitro.
specific cytotoxicity (% +/2 sem)
E : T ratio NOD-scid HHD islets NOD-scid islets
IGRP-T clone
Control T
clone IGRP-T clone
Control T
clone
30:1 14.763.2*$ 5.660.4 0.663.3 1.164.3
10:1 9.862.0* 0.363.3
Data represent the percent specific cytotoxicity against the indicated targets by
IGRP265–273-specific CD8 T cells. HLA-A2-restricted, tumor-antigen-specific CD8
T-cells were used as a control. 51Cr release from islets cultured in medium alone
(i.e. spontaneous release) for each target was measured in 9 independent wells
to calculate specific cytotoxicity as described in Materials and Methods. Data
are representative of 3 independent experiments.
*indicates a significant difference (p,0.01) in cytotoxicity against NOD-scid
islets tested at the same E:T ratio; $ indicates a significant difference (p,0.05) in
cytotoxicity against NOD-scid HHD islets between IGRP-specific CD8 T-cells and
control T-cells.
doi:10.1371/journal.pone.0049213.t001
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Cloning of IGRP265–273-specific CD8 T-cells
Peripheral blood mononuclear cells (PBMCs) from a HLA-
A*0201+ recent onset diabetic patient were incubated with A2/
IGRP tetramer on ice. One hour later, cells were incubated with
anti-CD8 for 20 min. A2/IGRP tetramer CD8 double-positive T-
cells were sorted and seeded at one cell per well in 96-well plates,
each well containing 16105 irradiated (50 Gy) allogeneic PBMCs,
56103 irradiated (100 Gy) IGRP265–273 peptide-pulsed HLA-A2-
expressing EBV-LCL in IMDM supplemented with 10% HS,
0.5% LeucoA, 0.1 ng/ml rh-IL12, 10 ng/ml rh-IL7, 25 U/ml rh-
IL2 and 5 ng/ml rh-IL15. T-cell clones were isolated and
restimulated every 2–3 weeks as described above. Every 3–4 days
fresh media containing 5 ng/ml IL-15 and 25 U/ml IL-2 were
added. From the panel of IGRP-reactive CD8 T-cell clones, we
selected one T-cell clone, termed clone 7 for further character-
ization.
ELISpot Assays
To determine secretion of IFNc, Granzyme B (GrB), and IL-10,
26104 clone 7 cells were incubated with HLA-A2-expressing
EBV-LCL pulsed with an IGRP-specific or a control peptide on
anti-cytokine (IFNc, GrB, and IL-10) antibody-precoated ELISA
plates and after o/n culture in IMDM supplemented with 1% HS,
plates were developed according to the manufacturer’s protocol
(U-CyTech, Utrecht, the Netherlands). Results are expressed as
means 6 SD of triplicate wells.
Analysis of CD107a Expression
Expression of CD107a on clone 7 cells was examined as
described by Betts et al [51].
Table 2. In-vivo lysis of peptide-pulsed HLA-A2 cell targets by IGRP-specific CD8 T-cells.
Lysis of peptide-pulsed targets (% +/2 sem)
Lysis of control targets
(% +/2 sem)
Experiment 1 13.762.1* 2.260.92
Experiment 2 21.8563.1* 3.2463.01
Data represent the percentage of specific cytotoxicity against IGRP-peptide pulsed HLA-A2 EBV-LCL by IGRP-specific CD8 T-cells in two independent experiments.
46106 IGRP-specific T cells were injected intrasplenically. One day later, mice received an i.v. injection containing of a 1:1 mixture of specific peptide-pulsed CFSEhi
target cells and control peptide-pulsed CFSElo target cells. At 20 hr, the ratio of CFSEhi and CFSElo cells in the spleens was analyzed by flow cytometry.
*indicates a significant difference (p,0.05) in cytotoxicity against control targets. In each experiment, 4 mice per group were used.
doi:10.1371/journal.pone.0049213.t002
Figure 3. IGRP-specific T-cells are able to infiltrate and destroy beta-cells following intra-pancreatic injection into NOD-scidIL2rcnull
HHD mice. NOD-scid IL2rcnull HHD recipient mice were injected i.v. with 206106 PBMC from an HLA-A*0201+ healthy donor. Two days later, these
mice were injected intra-pancreatically with either 56106 IGRP-specific T-cells (left), 56106 control T-cells (middle) or were sham injected (right). Four
weeks later, the pancreata were isolated and histologically examined. A, Sections of recipients of IGRP-specific or control T-cells, or of those receiving
a sham injection were stained with H&E (upper panel) to visualize the histological integrity of the islets or stained for insulin (middle panel) to identify
the beta cells or human CD45 (lower panel) to visualize the human T-cells. Similar data were obtained when staining sections for human CD8. B,
Pancreatic sections were stained for insulin, cCaspase-3 to detect apoptotic cells and DAPI to identify nuclei. Individual fluorescence as well as an
overlay is presented. Shown are representative examples of 5 mice per group.
doi:10.1371/journal.pone.0049213.g003
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Analysis of TCR-Va and Vb Repertoire by RT-PCR and
Sequence Analysis
Total RNA was isolated using RNA BEE (Tel-Test, Friends-
wood, TX). Random-primed cDNA was synthesized according to
manufacturer’s instructions (Roche, Indianapolis, IN). PCR
amplification of cDNA was performed with Ca or Cß reverse
primer (Ca: TgTgggAgATCTCTgCTTCTg,sequence Cß:
TCCTTCCCATTCACCCACCAgCTCAgCTC in combination
with a specific forward primer for Va or Vß TCR ([48] for primer
sequences). Control PCR amplifications for b-actin were per-
formed with each sample to confirm cDNA integrity. Aliquots of
each reaction were run on agarose gel prestained with ethidium
bromide, in order to compare amplicon intensities between
reactions. Appropriate dilutions were performed prior to analysis
when necessary. To establish whether clone 7 cells were mono-
clonal, PCR products were subjected to nucleotide sequence
analysis using ALFexpress sequencer (Pharmacia-Biotech, Swe-
den).
Cytotoxicity Assays
Standard 51Cr release assays were performed using HLA-A2+
EBV-LCL as target cells. Target cells were labeled with 51Cr
(100 mCi, Perkin Elmer, Billerica, MA) in the absence or presence
of 1 ug/ml specific or control peptide for 1 h at 37uC. After
extensive washing, cells were suspended in IMDM/10% HS and
3000 labeled target cells were co-incubated at effector to target
(E:T) ratios of 20:1, 5:1 and 1:1 in 96 well round-bottom plates in
triplicate for 4 h at 37uC. Controls included target cells incubated
in medium alone for spontaneous release and target cells in 5% (v/
v) Triton X-100 (Sigma, St. Louis, MO) in PBS for maximum
release. Radioactivity was measured by a Wallac Wizard 1470
Automatic Gamma Counter. The percentage of cytotoxic activity
was calculated using the following formula: % specific lysis = (-
sample cpm–spontaneous cpm)/(maximal cpm–spontaneous
cpm)6100%.
Cytotoxicity Assays Using Murine Islets as Targets
Cytotoxicity assays using intact mouse islets as targets were
performed as described previously [16]. Briefly, NOD-scid HHD
and NOD-scid pancreatic islets (10 islets/well) were allowed to
adhere in 96-well plates during a 10-day incubation at 37uC.
Adherent islets were labeled with 5 mCi/well of 51Cr for 3 h at
37uC. Islets were washed and overlaid with 100 ml of medium
containing various numbers of cultured clone 7 cells. For
establishing E:T ratios, each islet was assumed to contain 750
cells. A minimum of three wells were established for each E:T
ratio. Spontaneous release controls consisted of nine wells of
labeled islets from each donor cultured in the absence of T-cells.
Following a 20 h incubation at 37uC, the radioactivity in two
fractions from each well was measured. The first fraction was the
culture supernatant, the second was obtained by solubilizing the
remaining islets in 200 ml of 2% SDS. The percentage of 51Cr
release for each well was calculated by the formula [(supernatant
cpm)/(supernatant cpm + SDS lysate cpm)] x 100%. This allows
normalization for variation in the sizes of individual islets, which
could result in differences in the total levels of 51Cr incorporation
in each well. In turn, percent-specific cytotoxicity was calculated
by subtracting the percent 51Cr release from islets cultured in
medium alone (i.e., spontaneous release) from the release by each
well of islets cultured with a given number of T-cells.
In-vivo Cytotoxicity
To examine the cytotoxic potential of clone 7 cells in-vivo, an
established in-vivo cytotoxicity assay was used with modifications
[34;35]. PBMC from HLA-A*0201+ healthy donors were labeled
with either 2 mM or 0.2 mM CFSE (Sigma; CFSEhi and CFSElo
cells, respectively) for 15 minutes at 37uC. CFSEhi cells were
pulsed with 3 ug/ml IGRP265–273 peptide for 45 minutes at 37uC.
CFSElo cells were pulsed with a control peptide. Both cell
populations were washed, combined at equal ratios and 56106
cells of each population were intravenously injected into NOD-
scidIL2rcnull recipient mice via the tail vein. Recipient mice
received intrasplenic injections of indicated numbers of clone 7
IGRP-specific CD8 T cells or control T-cells 24 h earlier. Spleens
from recipient mice were harvested 20 hours after target cell
injection, and survival of each transferred population was assessed
by flow cytometry. A minimum of 16103 CFSE+ events were
collected from each sample. Specific cytolytic activity was
calculated using the following equation: [1– [(CFSEhi/CFSElo in
IGRP-T-cell recipients)/(CFSEhi/CFSElo in control T-cell reci-
pients)]6100.
Adoptive Transfer Experiments
NOD-scid IL2rcnull HHD recipient mice were injected i.v. with
206106 PBMC from a HLA-A*0201+ healthy donor. Two days
later, mice were injected intra-pancreatically with 56106 clone 7
cells, 56106 control tumor-antigen specific T-cells (PRAME-
specific T-cell clone) or sham injected. Blood glucose levels were
monitored twice weekly. After 4 weeks, pancreata were recovered
for histological analysis. Paraffin-embedded tissues were sectioned
at 4 mm and stained with hematoxylin and eosin (H&E) or used for
immunohistochemistry. Immune-stained tissues utilized antibodies
with specificity for insulin, human CD45 (DAKO, Carpinteria,
CA), and employed a standard avidin–biotin complex methodol-
ogy [52]. The sections were developed using 3-diaminobenzidine
and counterstained with hematoxylin for light microscopic
visualization. Alternatively, sections were incubated with guinea
pig anti-insulin that was visualized by staining with anti-guinea pig
IgG conjugated toAlexa-488 and rabbit anti-Caspase-3 antibody
that was visualized by staining with anti-rabbit IgG conjugated to
Alexa-594 (Invitrogen). Nuclei were visualized with DAPI and the
stain sections were analyzed using immunofluorescence microsco-
py. Control protocols included omission of primary antibodies and
the use of species-matched nonbinding control antibodies.
Statistical Analysis
Experimental groups were compared to controls using student’s
t-test. P,0.05 was considered significant.
Supporting Information
Figure S1 IGRP265–273 specifically binds to HLA-A2.
Peptide binding to HLA-A1, -A2, -A3 and –B8 was assessed
using a competition based binding assay [11]. The percentage of
fluorescent-labeled reference peptide bound to a specific HLA-
allele at different concentrations of unlabeled IGRP265–273 peptide
is shown. The IC50 value defines the concentration of IGRP265–273
peptide needed to inhibit 50% binding of the fluorescent-labeled
reference peptide. IC50 value HLA-A2:63 nM; IC50 value HLA-
A1, HLA-A3, HLA-B8:12590 nM.
(TIF)
Figure S2 IGRP-specific T-cells express adhesion mo-
lecules important for migration into inflamed pancreas
and secondary lymphoid tissue. IGRP-specific T-cells were
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stained with antibodies against TCRab, CD2, CD28, HLA-DR,
CD45RA, CD45RO, CXCR3, CCR4, CCR5, CCR7, CCR7
and CD62L and analyzed by flow cytometry. Dashed lines
represent isotype antibody staining, solid lines represent specific
antibody staining. These results are representation of 3 experi-
ments.
(TIF)
Table S1 Clone 7 IGRP/A2 binding T-cells cloned from
a type 1 diabetic individual are clonal. Clonality of IGRP-
specific clone 7 T-cells was determined by examining expression of
TCR Va and TCR Vb chains. Specific PCR with Ca or Cß
reverse primer in combination with a specific forward primer for
Va or Vß TCR revealed expression of Vb13c and Va19
transcripts in clone 7 T-cells. Control PCR amplifications for b-
actin were performed for each sample to confirm cDNA integrity.
Total RNA was isolated using RNA BEE (Tel-Test, Friendswood,
TX). Random-primed cDNA was synthesized according to
manufacturer’s instructions (Roche, Indianapolis, IN). PCR
amplification of cDNA was performed with Ca or Cß reverse
primer (Ca: TgTgggAg-ATCTCTgCTTCTg, sequence Cß:
TCCTTCCCATTCACCCACCAgCTCAgCTC in combination
with a specific forward primer for Va or Vß TCR ([48] for primer
sequences). Control PCR amplifications for b-actin were per-
formed with each sample to confirm cDNA integrity. Aliquots of
each reaction were run on agarose gel prestained with ethidium
bromide, in order to compare amplicon intensities between
reactions. Appropriate dilutions were performed prior to analysis
when necessary. To establish whether clone 7 cells were mono-
clonal, PCR products were subjected to nucleotide sequence
analysis using ALFexpress sequencer (Pharmacia-Biotech, Swe-
den).
(TIF)
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